Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

January 30, 2026

Conditions
Chronic Idiopathic Urticaria
Interventions
DRUG

UB-221

Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution

Sponsors

Lead Sponsor

All Listed Sponsors
lead

United BioPharma

INDUSTRY

NCT04175704 - Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter